B7-H3 (CD276): An Emerging Cornerstone Target in Cancer Immunotherapy – Supported by ANT BIO PTE. LTD.

1. Concept

B7-H3 (CD276), a key member of the B7-CD28 immunoregulatory protein family, is a type I transmembrane protein structurally analogous to programmed death-ligand 1 (PD-L1). It exhibits dual biological functions in immune regulation: early studies indicated its ability to stimulate T cell responses and promote interferon-γ (IFN-γ) production, while subsequent research has predominantly validated its role in inhibiting T cell activity. Characterized by two splice variants—2IgB7-H3 (B7-H3a) with one pair of immunoglobulin variable (IgV)-like and constant (IgC)-like domains, and 4IgB7-H3 (B7-H3b) with two pairs—B7-H3 shows species-specific expression: humans and other primates exclusively express the 4Ig variant, while mice primarily express the 2Ig form. With low expression in normal tissues and abnormal overexpression in various malignancies, B7-H3 contributes to tumor progression through multiple mechanisms, including immune evasion, enhancement of tumor cell invasion and migration, promotion of angiogenesis, and modulation of epigenetic modifications—establishing itself as a promising target for cancer immunotherapy.

2. Research Frontiers

Recent advances in B7-H3 research have accelerated its translation into clinical applications, with key frontiers focusing on mechanism elucidation, therapeutic innovation, and clinical validation:

• Receptor and Signaling Pathway Exploration: Despite its well-documented role in immune regulation, B7-H3’s specific receptors and downstream signaling cascades remain incompletely understood. Ongoing studies aim to identify its binding partners on T cells, natural killer (NK) cells, and other immune cells, which will inform the design of more precise targeted therapies.
• Novel Therapeutic Strategies: Multiple B7-H3-targeted approaches are under clinical investigation, including monoclonal antibodies (e.g., enoblituzumab), antibody-drug conjugates (ADCs; e.g., Omburtamab, MGC-018), bispecific/trispecific antibodies (e.g., XmAb-808), and chimeric antigen receptor (CAR)-T cell therapies. These strategies leverage B7-H3’s tumor-specific expression to enhance anti-tumor efficacy while minimizing off-target effects.
• Combination Therapy Optimization: Preclinical and clinical studies are exploring combinations of B7-H3-targeted agents with other immunotherapies (e.g., PD-1/PD-L1 inhibitors), chemotherapy, or radiotherapy to synergistically reverse immune suppression and improve treatment outcomes. For example, enoblituzumab combined with PD-1 inhibitors has shown promising activity in phase II trials.
• Biomarker Development: Research is evaluating B7-H3 expression levels as a predictive biomarker for treatment response. Tumor B7-H3 overexpression correlates with poor prognosis, reduced immune cell infiltration, and impaired T/NK cell function, making it a potential indicator for patient stratification in clinical trials.
• Toxicity and Resistance Management: Addressing treatment resistance (e.g., reduced B7-H3 expression, alternative immune evasion pathways) and minimizing toxicity (e.g., cytokine release syndrome in cell therapies) are critical focuses. Novel strategies include optimizing drug delivery systems and combining B7-H3-targeted therapies with agents that modulate the tumor microenvironment.

3. Research Significance

B7-H3 research holds profound significance for advancing cancer immunotherapy, addressing the unmet clinical need for effective treatments across various malignancies. Its tumor-specific expression pattern—low in normal tissues and high in tumors such as melanoma, glioma, and ovarian cancer—provides a unique safety window for targeted therapies, reducing the risk of adverse effects associated with conventional treatments.

From a biological perspective, understanding B7-H3’s dual role in immune regulation enhances our knowledge of tumor immune evasion mechanisms. Its ability to inhibit T/NK cell function, promote regulatory T cell (Treg) activity, and weaken NK cell cytotoxicity reveals novel pathways that tumors exploit to escape immune surveillance. This insight drives the development of strategies to restore anti-tumor immunity.

Translational research on B7-H3 has already led to the advancement of multiple therapies into clinical trials, offering new hope for patients with refractory or metastatic cancers. For the scientific community, B7-H3 serves as a model for exploring immune checkpoint biology, informing the development of targeted therapies for other understudied immunoregulatory molecules. Additionally, the development of B7-H3-specific reagents (antibodies, recombinant proteins) supports basic research and accelerates therapeutic development.

4. Related Mechanisms, Research Methods, and Product Applications

Core Mechanisms

• Immune Inhibition: B7-H3 suppresses anti-tumor immunity by multiple pathways: inhibiting T cell activation and cytokine (IFN-γ, IL-8) secretion, enhancing Treg-mediated immune suppression, and transmitting inhibitory signals to NK cells via binding to their surface receptors (e.g., NKp30), weakening their tumor-lytic capacity.
• Tumor Progression Promotion: Beyond immune evasion, B7-H3 enhances tumor cell invasion and migration, promotes angiogenesis, and modulates epigenetic modifications—all contributing to tumor growth and metastasis.
• Dual Immune Regulation: Under certain conditions, B7-H3 can also stimulate CD4+ and CD8+ T cell activation, highlighting its context-dependent dual functionality. However, its inhibitory role dominates in the tumor microenvironment.

Research Methods

• Expression Analysis: Techniques such as immunohistochemistry (IHC), flow cytometry, and quantitative PCR (qPCR) detect B7-H3 expression in tumor tissues, cell lines, and immune cells. Western blotting and ELISA quantify B7-H3 protein levels in biological samples.
• Functional Assays: In vitro assays (T/NK cell activation assays, cytokine secretion assays, Transwell migration/invasion assays) evaluate B7-H3’s effects on immune cell function and tumor cell behavior. In vivo xenograft models assess the anti-tumor efficacy of B7-H3-targeted therapies.
• Receptor and Signaling Studies: Co-immunoprecipitation, surface plasmon resonance (SPR), and gene silencing (siRNA/shRNA) are used to identify B7-H3 receptors and dissect downstream signaling pathways (e.g., NF-κB, NFAT).
• Therapeutic Efficacy Evaluation: Preclinical studies measure tumor growth inhibition, survival rates, and immune cell infiltration after treatment with B7-H3-targeted agents. Clinical trials assess safety, efficacy, and biomarkers of response.

Product Applications by ANT BIO PTE. LTD.

ANT BIO PTE. LTD. provides a comprehensive portfolio of research tools through its specialized sub-brands to support B7-H3-focused studies and therapeutic development:

• STARTER Brand (Antibodies): Offers a diverse range of B7-H3-specific antibodies, including recombinant rat anti-mouse CD276 mAb (S0B1361), recombinant rabbit mAbs (S0B2244, S0B2334, S0B2169), and antibody panels (S0C2022, S0C201, S0C2019) targeting B7-H3 in combination with immune cell markers (CD4, CD8α, Granzyme B). These antibodies are optimized for IHC, flow cytometry, and Western blotting, enabling precise detection and functional analysis of B7-H3.
• UA Brand (Recombinant Proteins): Supplies high-purity recombinant B7-H3 proteins from multiple species (human, mouse, cynomolgus) with various tags (His, Biotin-Avi, Fc), including UA010328 (Biotinylated Human B7-H3), UA010010 (Human B7-H3 His Tag), and UA010639 (Human 4Ig B7-H3 Fc Chimera). These proteins are critical for receptor binding studies, antibody screening, and functional assays.
• Absin Brand (Kits & General Reagents): Provides ELISA kits for quantifying B7-H3 and related cytokines (IFN-γ, IL-10, TGF-β), as well as general reagents for cell culture, immune cell isolation, and protein extraction—streamlining experimental workflows for B7-H3 research.

5. Brand Mission

At ANT BIO PTE. LTD., our mission is to empower global life science researchers, oncologists, and translational scientists by delivering high-quality, reliable reagents and tools that accelerate breakthroughs in cancer immunotherapy and immune biology. We are committed to supporting the exploration of pivotal targets like B7-H3 through our specialized sub-brands: STARTER (high-specificity antibodies), UA (high-purity recombinant proteins), and Absin (reliable kits & general reagents). Leveraging advanced development platforms—including recombinant rabbit/mouse monoclonal antibody technology, multi-system protein expression (E.coli, CHO, HEK293, Insect Cells), and One-Step ELISA platforms—we adhere to rigorous quality standards (compliant with EU 98/79/EC, ISO9001, and ISO13485 certifications) to ensure product consistency, specificity, and performance. Our dedication to innovation, quality, and customer-centricity drives us to contribute to advancements in cancer diagnosis, treatment, and personalized medicine, ultimately improving the lives of cancer patients worldwide.

6. Related Product List

7. AI Disclaimer

This article is AI-compiled and interpreted based on the original work. All intellectual property (e.g., images, data) of the original publication shall belong to the journal and the research team. For any infringement, please contact us promptly and we will take immediate action.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.